Celltrion USA Patent-Cliff Exposure & CMS Drug Spending Portfolio

Celltrion USA (US): 3 reconciled FDA prescription therapies, $23.8M 2024 CMS Part D & Medicaid spend, and $3,277 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies3
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$23.8M
2024 Medicare Part D Spend$22.5M
2024 Medicaid Spend$1.3M
California HCAI SB 17 FilingsSpecialty launch notice ($3,277 intro WAC)